Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK

被引:0
|
作者
Rothnie, Kieran J. [1 ,7 ]
Numbere, Beade [1 ]
Gelwicks, Steven [2 ]
Lu, Yifei [1 ,3 ]
Sharma, Raj [4 ]
Compton, Chris [4 ]
Ismaila, Afisi S. [2 ,5 ]
Quint, Jennifer K. [6 ]
机构
[1] GSK, Value Evidence & Outcomes, R&D Global Med, London, England
[2] GSK, Value Evidence & Outcomes, R&D Global Med, Collegeville, PA USA
[3] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC USA
[4] GSK, Global Med, London, England
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[6] Imperial Coll London, Natl Heart & Lung Inst, London, England
[7] GSK, Value Evidence & Outcomes, R&D Global Med, 980 Great West Rd, Brentford TW8 9GS, Middlesex, England
关键词
COPD; CPRD; exacerbation; GOLD A/B; risk factor; UK; OBSTRUCTIVE PULMONARY-DISEASE; HEALTH-CARE; PREDICTION; OUTCOMES;
D O I
10.2147/COPD.S413947
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose: Risk factors for exacerbations of chronic obstructive pulmonary disease (COPD) have been previously characterized for patients with more severe cases of COPD. It is unclear how the risk of first exacerbation may best be identified in patients with less severe disease. This study investigated risk factors for first exacerbation among English patients with COPD classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) group A or B. Patients and Methods: A retrospective cohort study using data from the UK Clinical Practice Research Datalink (CPRD) AURUM linked to Hospital Episode Statistics. Patients with COPD aged >= 35 years and classified as GOLD group A or B (2020 criteria) from January 2013-December 2019 were eligible. Patients were required to have 24 months history in CPRD (baseline). Two cohorts were defined: cohort 1 included patients with no severe exacerbations during baseline; cohort 2 included patients with no moderate or severe exacerbations during baseline. Risk factors associated with severe, or combined moderate and severe exacerbation were examined for up to 5 years of follow-up. Results: Overall, 194,948 patients were included in cohort 1 (mean age 66.2 years; 55.2% male), and 148,396 patients in cohort 2 (mean age 66.1 years; 56.6% male). Identified risk factors for exacerbation (and associated 1-year absolute risk of severe, or combined moderate and severe exacerbation, respectively) included: Medical Research Council dyspnea scale score (15.9%/28.4%); COPD Assessment Test score (9.6%/25.3%); GOLD grade of airflow limitation (forced expiratory volume in 1 second % predicted; 13.6%/27.5%); and lung cancer (8.1%/23.6%). After adjustment for risk factors, these factors remained independently associated with severe exacerbation at 1, 3, and 5 years of follow-up. Conclusion: The identified risk factors may aid physicians in the early recognition of patients with COPD classified as GOLD group A or B at risk of first exacerbation.
引用
收藏
页码:2673 / 2685
页数:13
相关论文
共 50 条
  • [41] Clinical characteristics and risk factors associated with secondary bacterial pneumonia among COVID-19 patients in ICU
    Iscanli, Insa Gul Ekiz
    Aydin, Mehtap
    Saylan, Bengu
    JOURNAL OF INFECTION IN DEVELOPING COUNTRIES, 2023, 17 (10): : 1387 - 1393
  • [42] Identifying novel factors beyond prior hospitalisations, including biomarkers, associated with future asthma hospitalisation risk from routine UK primary care clinical records
    Price, D. B.
    Bleecker, E. R.
    Campbell, J. D.
    Corrigan, C. J.
    Pavord, I. D.
    Wenzel, S. E.
    Thomas, M.
    Wilson, A. M.
    Clark, A.
    Rigazio, A.
    Burden, A.
    Ashton, V. L.
    Gopalan, G. H.
    Small, Buatti M.
    ALLERGY, 2014, 69 : 61 - 61
  • [43] Clinical factors associated with the use of NIV in the pre-hospital setting in adult patients treated for acute COPD exacerbation: a single-center retrospective cohort study
    von During, Stephan
    Chevalley, Benjamin
    Wozniak, Hannah
    Desmettre, Thibaut
    Quintard, Herve
    Suppan, Laurent
    Fehlmann, Christophe A.
    BMC EMERGENCY MEDICINE, 2025, 25 (01):
  • [44] Prevalence of coronary risk factors in contemporary practice among patients undergoing their first percutaneous coronary intervention: Implications for primary prevention
    Gurm, Zoya
    Seth, Milan
    Daher, Edouard
    Pielsticker, Elizabeth
    Qureshi, M. Imran
    Zainea, Mark
    Tucciarone, Michael
    Hanzel, George
    Henke, Peter K.
    Sukul, Devraj
    PLOS ONE, 2021, 16 (06):
  • [45] Factors Associated With Adherence to First-line Antiviral Therapy Among Commercially Insured Patients With Chronic Hepatitis B
    Alpern, Jonathan D.
    Joo, Heesoo
    Bahr, Nathan C.
    Leventhal, Thomas M.
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (03):
  • [46] CLINICAL RISK FACTORS ASSOCIATED WITH THE DEVELOPMENT OF SYSTEMIC DISEASE IN PATIENTS WITH ISOLATED HLA-B27 UVEITIS
    Vazquez-Trinanes, C.
    Rivera, A.
    Freire, M.
    Alonso, M.
    Villaverde, I.
    Perez-Rodriguez, M.
    del Pozo, M.
    Sopena, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 200 - 200
  • [47] Factors Associated With The Prescription Of Inhaled Corticosteroids In The Current Gold Groups A And B COPD Patients - Subgroup Analysis Of The Taiwan Obstructive Lung Disease (told) Cohort
    Wei, Y. -F.
    Kuo, P. -H.
    Tsai, Y. -H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [48] Factors associated with adherence to guidelines of good clinical practice during hospital treatment of patients with the first episode of schizophrenia spectrum disorders
    Stasevic, Milena
    Karlicic, Ivana Stasevic
    Divac, Nevena
    Grgurevic, Anita
    Grbic, Igor
    VOJNOSANITETSKI PREGLED, 2019, 76 (10) : 998 - 1006
  • [49] A study on hepatitis B viral seromarkers and associated risk factors among the patients suffering from acute and chronic hepatitis B infection
    Prabina, P.
    Jayanthi, S.
    Murthy, C. Krishna
    Kumar, S. Babu
    Banu, A. S. Shameem
    Sakunthala, S. R.
    Perumal, J.
    INTERNATIONAL JOURNAL OF APPLIED AND BASIC MEDICAL RESEARCH, 2019, 9 (04) : 206 - 211
  • [50] Adjunctive therapy with pramlintide in insulin-treated patients with type 2 diabetes improved glycemic control and cardiometabolic risk factors in routine clinical practice
    Bhushan, Rajat
    Elkind-Hirsch, Karen E.
    Bhushan, Madhu V.
    Butler, William J.
    Hirsch, David E.
    DIABETES, 2007, 56 : A557 - A557